Complete Response Letter Issued to First Deuterated Drug Under FDA Review

The NDA proposes a novel treatment for chorea associated with Huntington's disease
The NDA proposes a novel treatment for chorea associated with Huntington's disease

Teva announced that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of SD-809 (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease (HD). SD-809 is the first deuterated agent to be reviewed by the FDA.

The letter included a request from the FDA to examine blood levels of certain metabolites that are similarly seen in patients receiving tetrabenazine or deutetrabenazine. No new clinical trials have been requested.

Related Articles

SD-809 is also under development for the treatment of tardive dyskinesia (TD) and Tourette syndrome (TS). A Phase 3 clinical trial for patients with moderate to severe TD is currently ongoing. Previously, FDA granted Orphan Drug designation to SD-809 for the treatment of HD and for the treatment of tics associated with TS in the pediatric population.

SD-809 (deutetrabenazine) is an investigational, oral, small-molecule, vesicular monoamine 2 transporter (VMAT2) inhibitor which utilizes Teva's deuterium technology.

For more information call (888) 838-2872 or visit Tevausa.com.

Loading links....